Background We report clinical safety and biochemical effi cacy from a dose-ranging study of intravenously administered AVI-4658 phosphorodiamidate morpholino oligomer (PMO) in patients with Duchenne muscular dystrophy.
Introduction
Duchenne muscular dystrophy is a progressive, severely disabling neuromuscular disease that aff ects one in 3500 newborn boys and causes premature death. 1 In Duchenne muscular dystrophy, the open reading frame of the X-linked dystrophin gene (DMD) is disrupted by deletions (roughly 65%), duplications (10%), point mutations (10%), or other smaller rearrangements. Dystrophin is located underneath the sarcolemma and assembles with sarcolemmal proteins such as dystroglycan, α-sarcoglycan, and neuronal nitric oxide synthase (NOS) to form the dystrophin-associated glyco protein complex. The essential function of dystrophin in muscle is to connect the subsarcolemmal cytoskeleton to the sarcolemma by binding N-terminally to F-actin and C-terminally to β-dystroglycan. Loss of dystrophin results in infl ammation, muscle degeneration, and replacement of muscle with fi broadipose tissue. 2 In the milder allelic Becker muscular dystrophy, dystrophin mutations do not disrupt the open reading frame, a shortened but functional dystrophin protein is produced, and most patients are able to walk into late adulthood and have a normal lifespan. 3 Therefore, induction of exon skipping to restore the open reading frame is an attractive therapeutic strategy in Duchenne muscular dystrophy that can be achieved with spliceswitching oligomers. These oligomers are typically 20-30 nucleotides in length and are complementary in sequence to regions of the pre-mRNA transcript relevant for targeted DMD exon skipping. 4 Spliceswitching oligomers targeting dystrophin exons have been successfully used to restore dystrophin expression in vitro and in various animal models of Duchenne muscular dystrophy. 5, 6 In the mdx mouse, adminis tra tion of 2´O-methyl-ribooligonucleosidephosphorothioate (2´OMe) and phosphorodiamidate morpholino oligomers (PMOs) identifi ed PMOs as more eff ective for induction of exon skipping and restoration of long-lasting dystrophin production after intramuscular or intravenous administration. 7 In the X-linked muscular dystrophy dog, PMO administration was followed by dystrophin restoration and clinical benefi t without adverse reactions. 6 Two proof-of-principle clinical trials in patients with Duchenne muscular dystrophy, who received one intramuscular administration of either 2´OMe 8 or PMO 9 targeted to skip exon 51, showed effi cient dystrophin restoration. More recently, in an open-label, doseescalation study in 12 boys with Duchenne muscular dystrophy, 10 weekly subcutaneous injections of PRO051, a 2ÓMe splice switching oligomer, at 0·5, 2, 4, and 6 mg/kg bodyweight for 5 weeks induced skipping of exon 51 and increased dystrophin concentrations. A 12-week extension with a dose of 6 mg/kg bodyweight of PRO051 10 was well tolerated and was followed by stabilisation of muscle function, but no signifi cant improvement in a 6-min walk test. We report biochemical effi cacy and clinical safety from a dose-ranging study of the fi rst intravenous systemically administered PMO, AVI-4658, in patients with Duchenne muscular dystrophy.
Methods

Study design and participants
This open-label phase 2 study was approved by the UK Medicines and Healthcare Products Regulatory Agency. The UK Gene Therapy Advisory Committee provided ethics approval and site-specifi c approval under the number GTAC157 (EudraCT number 2007-004695-39) for both active trial sites in London and Newcastle, UK. Additionally, the study was adopted by the institutional review boards at both sites. Participants were aged 5-15 years and had genetically confi rmed diagnosis of Duchenne muscular dystrophy with an out-of-frame deletion eligible for correction by skipping of exon 51. The absence of additional deletions and variants in the splice switching oligomer duplex formation region was confi rmed in all participants by dystrophin exonic multiplex ligation-dependent probe amplifi cation and DNA sequencing. Participants were enrolled after written informed assent from the child and written informed consent of a parent or legal guardian was obtained. Further study details are shown in the webappendix pp 1-3; the protocol is available online. If no original diagnostic muscle biopsy sample was available, a sample was obtained from the biceps brachii muscle (16 participants) and a post-treatment sample was taken from the contralateral biceps 2 weeks after the last dose of the study drug. Figure 1 shows the dose escalation and cohort assignment. The data safety monitoring board met with clinical investigators and the sponsor to review safety before dose escalations took place. Each cohort led with a single patient and, after three doses, a safety monitoring committee consisting of clinical investigators, the sponsor medical monitor, and the medical study monitor reviewed all safety data from that patient before enrolment of subsequent patients to expand that cohort. Dose escalation occurred after informed discussion of the data safety monitoring board when all patients in the previous cohort had received at least 3 weeks of treatment.
Procedures
AVI-4658 (sequence CTCCAACATCAAGGAAGATGGC-ATTT CTAG), 11 an exon 51-targeting PMO, was provided by AVI BioPharma (Bothell, WA, USA) at 100 mg/mL in phosphate-buff ered saline (1 mL/vial). It was diluted in P17  P16  P15  P14  P13  P12  P11  P10  P9*  P8  P7  P6  P5  P4  P3  P2  P1   6710  10 788  5673   3036  1342  2801  864  924  1113  255  326   6982  4866  6207  2664   180  218  171  186   11  12  12  12  12  12  12  12  12  11  7  12  12  12  12  10  12  12  12   9  10  7  9  10  12  7  6  9  10  10  9  13  6  6  8  8  8  9 45 up to 50 mL saline (NaCl 0·9% v/w) for intravenous infusion over 1 h. Exon 51 skipping in muscle biopsy samples was assessed by RT-PCR. 9 Dystrophin expression in pretreatment and post-treatment muscle was investigated fi rst by immunohistochemical detection of dystrophin with MANDYS106 12 (MDA Monoclonal Antibody Resource, Glenn Morris, Oswestry, UK) and Dys2 (Novacastra, UK) antibodies, initially assessed by two masked investigators. To control for the presence of trace levels of dystrophin in the pretreatment muscle, as well as revertant fi bres, 13, 14 we set a baseline using sections of pretreatment muscles from each patient when counting dystrophin-positive fi bres in post-treatment muscles, so that only any revertant fi bres were seen as positive. We then used this threshold to count the dystrophin-positive fi bres in sections of post-treatment muscle of that patient. 2 The investigator had to be unmasked to which section came from the pretreatment and post-treatment biopsies. The semi quantitative measurements of dys trophin, α-sarcoglycan, and neuronal NOS expression levels were done as previously described. 13 Finally, western blotting was done with the antidystrophin antibody Dys1 15 and quantifi ed as explained in the webappendix p 4.
Infl ammatory infi ltrates in muscle biopsy samples were examined by immunohistochemistry with antibodies against CD3 pan T cells, CD4 T-helper cells, and CD8 cytotoxic T cells (webappendix p 3). Antidystrophin antibody induction in patients' sera was tested at week 1 and week 12. 9 Pharmacokinetic parameters of AVI-4658 were established from plasma and urine taken over 24 19 ) was undertaken to identify any dose-dependent changes.
The primary objective of this study was to assess the safety of systemic administration of escalation of doses of AVI-4658. The secondary objectives were to investigate the pharmacokinetics of AVI-4658 and the biochemical effi cacy as assessed by induction of dystrophin expression in muscle. The functionality of restored dystrophin was assessed by study of both the relocalisation of dystrophinassociated glycoprotein complex proteins to the sarcolemma and the eff ect of restored dystrophin on muscle infl ammation.
Statistical analysis
No formal sample size calculations were done. All descriptive statistical analyses were done with Graph Pad Prism 4 statistical software. We calculated p values using a paired t test to compare pretreatment versus posttreatment samples. The exact Cochran-Armitage trend test was used to show the dose response to AVI-4658.
The study was registered at ClinicalTrials.gov, number NCT00844597.
Role of the funding source
The UK Medical Research Council funded the study teams, patients' travel, and the acquisition and analysis of the clinical and biochemical outcome measures. AVI BioPharma funded the regulatory submission, the study sponsorship including clinical and medical monitoring, data collection, and provision of the study drug. FM, KB, SC, and SBS had complete access to the data and FM as corresponding author was responsible for submission for publication.
Results
19 patients were enrolled within the UK: 12 at Great Ormond Street Hospital for Sick Children (London) and seven at the Royal Victoria Infi rmary (Newcastle). Participants fulfi lled eligibility criteria, had a mean age of 8·7 years (range 6-13), and had the clinical phenotype of Duchenne muscular dystrophy (table 1). A pretreatment muscle biopsy confi rmed less than 5% revertant fi bres in all patients. Adverse events were generally mild (63%) to moderate (32%), consistent with complications related to the disorder and to the paediatric age range, and showed no dose-dependent increase in frequency or severity (webappendix p 7). Diffi cult venous access largely due to cushingoid features resulted in failure to administer four of the planned 228 doses. Five other doses were not administered because of an adverse event in participant P9 leading to discontinuation of treatment after the seventh dose. In total, 219 doses of AVI-4658 were administered. Participant P11 was enrolled to ensure that at least two participants in each cohort (dose) completed the dosing period and had a post-treatment muscle biopsy.
The 219 intravenous PMO administrations, including cannulation, were generally well tolerated. Laboratory safety assessments did not show any eff ect of AVI-4658 on pulmonary, kidney, liver, or bone-marrow functions. We did not identify any widespread rash or other clinical signs indicating an adverse reaction; four infusions were associated with a local rash due to application of local anaesthetic cream before venepuncture. Two serious adverse events were reported, both unrelated to the study drug (table 1). Participant P9 had normal cardiac fractional shortening (34%) before study entry, although mild regional impairment of the left ventricular inferior segment was detected on Doppler imaging. Over the fi rst few weeks of study treatment, mild intermittent sinus tachycardia (maximum 125 beats per min) was noted. After the seventh dose, an echocardiogram revealed that his fractional shortening had fallen to 22%, and treatment with ACE inhibitor and β blocker was started. The investigators and study sponsor agreed to discontinue PMO administration and that this patient should not undergo general anaesthesia for the posttreatment muscle biopsy. At the fi nal visit at week 26, his heart function had stabilised with a fractional shortening of 26%. This complication was judged most likely to be part of the well described pattern of cardiomyopathy associated with Duchenne muscular dystrophy. Cardiac investi gations in the remaining participants were consistent with fi ndings in the disorder. Forced vital capacity did not change signifi cantly during the study (webappendix pp [10] [11] 24) . Creatine kinase concentrations did not show any dosedependent trends. There was no induction of antidystrophin antibodies after treatment (data not shown). Muscle function testing did not reveal any dosedependent changes (webappendix pp 12-21, 25-27). These assessments showed that most patients remained stable during the study period; four lost ambulation during follow-up, as was expected on the basis of their ambulatory stage at study entry (table 1) .
The plasma half-life of AVI-4658 was short (1·62-3·60 h; fi gure 2), and no accumulation between doses was recorded. Clearance was 233-615 mL/h per kg, and volume of distribution was 450-981 mL/kg. As a result of the small sample size, a clear relation between dose and clearance and volume of distribution could not be established. Renal clearance of AVI-4658 ranged between 116 and 229 mL/h per kg and was between 32·3% and 46·2% of total (plasma) clearance at doses between 0·5 and 4 mg/kg. At 10 and 20 mg/kg doses, renal clearance accounted for 60·5% and 63·8% of total clearance from the plasma in the fi rst 24 h after dosing.
Experiments on MyoD-converted patient fi broblasts treated with a 2´OMe congener of AVI-4658 were done in all participants 11 to confi rm before the trial that the patients were able to correctly skip exon 51. This preliminary step was done with a 2ÓMe antisense oligonucleotide because PMO cannot be used to transfect cells in culture, whereas 2´OMe can be effi ciently delivered by transfection. The results of this experiment were positive in all patients' cells and no qualitative diff erences in exon skipping between patients were noted (data not shown). When post-treatment muscle biopsies were assayed by RT-PCR, all patients had variable AVI-4658 induced skipping of exon 51, confi rmed by sequencing (webappendix p 22).
Seven patients had a post-treatment increase in dystrophin protein expression compared with their pretreatment biopsies, evidenced by at least two of the three methods of quantifi cation: number of dystrophinpositive fi bres, western blotting, and semiquantitative immunocytochemistry measurements (fi gure 3, Pretreatment muscle biopsy samples from participants P1, P3, and P6 were diagnostic quadriceps samples at the time of diagnosis, all other samples were obtained from the biceps muscle. Participant P4, who had missed two PMO doses because of cannulation challenges, declined the post-treatment muscle biopsy, but completed the rest of the study. Participant P9 did not undergo general anaesthesia for the post-treatment muscle biopsy because of an adverse event (cardiomyopathy) and was discontinued from treatment after week 7. Participant P11 was enrolled in cohort 4 to substitute for P9. Therefore, only 17 of 19 post-treatment muscle biopsy samples were obtained and participants P4 and P9 are not listed in this table. PMO=phosphorodiamidate morpholino oligomer.*Mean fl uorescence signal intensity of MANDYS106 12 as percentage of control muscle (details in webappendix p 23). †Response to AVI-4658: + shows response at RNA level (exon 51 skipping), but without detectable increase of dystrophin expression in post-treatment muscle biopsy; ++ shows response at RNA level and increase of dystrophin expression in post-treatment muscle; and +++ shows response at RNA level and increase in post-treatment muscle biopsy sample with all three methods of dystrophin quantifi cation. ‡Two-tailed t test comparing the mean fl uorescence intensity in the pretreatment versus post-treatment biopsy sample for each patient; we assessed the dose response to AVI-4568 across cohorts using the Cochran-Armitage method and confi rmed a signifi cant linear trend of dose response leading to increase in dystrophin expression (responders with ++ or +++) with increasing dose (p=0·0203). webappendix p 23). In these seven patients, mean dystrophin fl uorescence intensity increased from 8·9% (95% CI 7·1-10·6) to 16·4% (10·8-22·0) of normal control after treatment (p=0·0287). In the low-dose cohorts 1 to 4, there was no increase in dystrophin expression, with the exception of participant P7 in cohort 3. However, six of eight patients in the two high-dose cohorts 5 and 6 showed an increase in protein expression. Three patients, one in each of cohorts 3 (P7), 5 (P15), and 6 (P18), had a very substantial response to AVI-4658, having 21%, 15%, and 55% dystrophin-positive fi bres, respectively. These three patients had also 314%, 198%, and 110% increases in dystrophin intensity compared with pretreatment biopsy on semiquantitative immunocytochemistry. 13 Western blot analysis of these patients also showed an increase after treatment of protein levels from 2% to 18%, from 0·9% to 17%, and from 0% to 7·7% of normal muscle, respectively (table 2) . A dose-dependent signifi cant linear increase in dystrophin expression was noted (table 2; exact Cochran-Armitage trend test, p=0·0203). Additionally, AVI-4658 administration induced signifi cant increase of dystrophin expression on immunocytochemistry pretreatment versus post-treatment in cohorts 5 and 6 (paired twosided t test, p=0·04). Participant P19 had dystrophin levels on blot of 12·3% of control muscle, but a smaller increase in fl uorescence intensity and percentage of dystrophin-positive fi bres, probably refl ecting variability in diff erent blocks of the muscle biopsy sample studied with the diff erent techniques (table 2). The functional properties of restored dystrophin were confi rmed by quantifi cation of α-sarcoglycan and neuronal NOS expression. Dystrophin-positive fi bres had roughly a 30% average increase in α-sarcoglycan expression compared with dystrophin-negative fi bres in the patient with the best response to treatment, P18 (deletion 49-50). Dystrophin restoration was followed by restoration of neuronal NOS at the sarcolemma, more so in patients with exon 49-50 deletions than in those with 45-50 deletions (fi gure 4A), which is consistent with the observation that the neuronal NOS binding domain is located in dystrophin exons 42-45. 20, 21 Finally, the infl ammatory infi ltrate was investigated to establish whether dystrophin restoration had any eff ect on the prominent infl ammatory response seen in Duchenne muscular dystrophy (fi gure 4B). 22 A reduction in infl ammatory infi ltrates was recorded in cohorts 5 and 6, apart from in participant P15 in whom the CD8 cell count was increased, but not around dystrophinpositive fi bres. Furthermore, this patient did not have antidystrophin antibodies. Despite the small number of samples, the signifi cant reduction in CD3 cell count (paired two-tailed t test, p=0·0115) shows that restored dystrophin is tolerated by the immune system. The quotient between CD3% and dystrophin intensity in the seven patients who responded to treatment showed a signifi cant reduction in the post-treatment muscle biopsy samples (one-tailed paired t test, p=0·0078), confi rming the correlation with the increase in dystrophin expression.
Discussion
We show for the fi rst time that repeated systemic administration of a PMO splice switching oligomer (AVI-4658) induces targeted exon skipping in skeletal muscle in patients with Duchenne muscular dystrophy, restoring correctly localised dystrophin at the sarcolemma (panel). The administration of AVI-4658 was very well tolerated, without clear drug-induced adverse events with single doses of up to 900 mg and cumulative exposure exceeding 10 000 mg. The absence of drug-related adverse events after 12 weeks is encouraging, but caution is still needed because any splice switching oligomer would need to be given lifelong.
A clear and signifi cant dose response was recorded in terms of dystrophin protein expression, leading to seven patients who responded to treatment at higher doses. This fi nding was accompanied by a signifi cant reduction of infl ammatory infi ltrates in patients in the two highest dose cohorts. Patients with the highest levels of dystrophin also had increased sarcolemmal expression of proteins of the dystrophin-associated glycoprotein complex. This outcome included restoration of neuronal NOS to the sarcolemma in patients with deletions that did not disrupt the NOS binding site 20 localised in spectrin repeats 16/17 of the rod domain. The restoration of neuronal NOS is benefi cial for patients in whom ongoing muscle damage is compounded by paradoxical exercise-induced vasoconstriction 23 as a result of dysfunctional fi ne-tuning of blood fl ow. 20 The reduced infl ammation in muscle could be related to reduced necrosis due to improved sarcolemmal function with better resistance to mechanical load, induced by the restored dystrophin. 24 We noted variable levels of protein restoration in the seven patients who responded to treatment and considered possible reasons for this variability. Variability due to specifi c deletions and intronic breakpoints of individual patients could not be detected in vitro, because the response to splice switching oligomer in all patients' myotubes was qualitatively similar. The stability of the resulting protein might be relevant 21 since the patients with the three greatest responses to treatment all had 49-50 deletions and mildly aff ected patients with Becker muscular dystrophy or even asymptomatic individuals with deletion of exons 49-51 have been described, 25 suggesting that this shortened protein is highly functional. However two patients who did not respond to treatment (cohort 1, P3, who had no increase in either dystrophin-positive fi bres or dystrophin expression, and cohort 3, P8, who had an increase in dystrophin-positive fi bres, but not in dystrophin expression) and one with a small response (cohort 5, P12) also have the deletion 49-50; additionally, patients with exon 45-50 deletions did not have more protein than did patients with other genotypes, although asymptomatic individuals with 45-51 deletions are on record. [26] [27] [28] An aspect to consider is the genetic background, which in humans is variable, including the intronic deletions breakpoints. A further variable could be diff erences in pharmacodynamics of PMO, although our analysis suggests that there was not a clear correlation between response and maximum concentration and area under the curve for AVI-4658. When concomitant treatments, age, and extent of muscle pathological changes were taken into account, no obvious pattern emerged. Immune response to novel dystrophin epitopes induced by exon skipping could be another reason for the variability; however, this explanation seems unlikely because we did not detect humoral immunity in any of the patients and furthermore we documented a reduction in T cells in muscle biopsy samples in cohorts 5 and 6, who showed the highest dystrophin levels.
In a recent systemic exon skipping trial in Duchenne muscular dystrophy using the 2´OMe chemistry, high numbers of dystrophin-positive fi bres but low dystrophin levels were described. 10 However, the study had no pretreatment muscle biopsy in patients in whom a dystrophin response was reported, making establishment of a proper baseline to distinguish minimally positive from negative fi bres diffi cult. Indeed, in Duchenne muscular dystrophy, sections of muscle often have discernible trace levels after immunostaining with the antibodies to dystrophin used, 9, 13 and these pretreatment levels need to be taken into account to provide an accurate measurement of both number of positive fi bres and dystrophin intensity. 9, 10, 13 In our study, we fi rst established the level of dystrophin in the pretreatment muscle biopsy sample, and regarded those levels as the baseline for that individual-ie, judged fi bres as positive only if they exceeded the intensity levels of the pretreatment biopsy.
With respect to the variable dystrophin restoration we have reported, the most plausible conclusion is that stochastic events aff ect muscle splice switching oligomer targeting and contribute to variability. Animal models treated with both 2´OMe and PMO also showed substantial variability of dystrophin expression, even in contralateral muscles from the same animal. 5, 29 Because splice switching oligomers do not target skeletal muscle specifi cally, their uptake is partly dependent on local events such as muscle perfusion, damage, and infl ammation. To obtain more uniform protein production, either high doses of PMO or prolonged frequent administration, or both, could be considered because PMOs seem to be well tolerated. 30 The safety profi le we noted with AVI-4658 at doses of 20 mg/kg, supported by animal testing at up to human equivalent doses of 100 mg/kg, 30 is encouraging and bodes well for longer administration periods and higher clinical dose. Preclinical data suggest that repeated administration of even small doses over an extended time achieves more homogeneous restoration of dystrophin than does the same cumulative dose administered as a bolus injection of PMO. 31 This fi nding suggests that a long period of administration will be necessary to achieve homogeneous dystrophin expression.
In terms of the clinical effi cacy, the PRO051 study 10 claims that eight of 11 boys who were ambulant at entry to the extension study showed improvement in the 6-min walking test of 35·2 m (SD 28·7) after 12 weeks' treatment; however, this change was not signifi cant. Moreover, several of these children were younger than 7 years and, according to longitudinal observation, 19 boys younger than 7 years with Duchenne muscular dystrophy gain motor function. Additional confounding factors are the variability in the walking test (SD 36 m 19 ) and the
Panel: Research in context
Systematic review
We searched PubMed in March, 2011, using the keywords "Duchenne", "antisense", "exon skipping", and "clinical trial". Splice-switching oligomers have been tested previously after intramuscular injection in animal models and in patients aff ected by Duchenne muscular dystrophy. 6, 8, 9 An open-label, dose-escalation study 10 in 12 boys with Duchenne muscular dystrophy receiving weekly subcutaneous injections of the 2´OMe PRO051 at 0·5, 2, 4, and 6 mg/kg bodyweight for 5 weeks induced skipping of exon 51. Low dystrophin levels were reported after treatment, although the absence of pretreatment samples makes precise quantifi cation of the biochemical effi cacy of PRO051 diffi cult. This study was followed by a 12-week extension study using a dose of 6 mg/kg bodyweight of PRO051, with stabilisation of muscle function, but no signifi cant improvement in a 6-min walk test.
Interpretation
We report for the fi rst time that the systemic administration of a splice-switching oligomer based on PMO chemistry (AVI-4658) induced restoration of dystrophin expression in skeletal muscle of boys with Duchenne muscular dystrophy. The clinical and laboratory safety data in our open-label, dose-escalation, repeated intravenous administration study showed that AVI-4658 was well tolerated. Seven patients had a signifi cant dose response, six of whom were in the two high-dose cohorts, showing restoration of dystrophin protein expression. This fi nding was associated with increased expression of proteins associated with dystrophin, such as α-sarcoglycan and neuronal nitric oxide synthase, the sarcolemmal localisation of which is disrupted in Duchenne muscular dystrophy. Additionally, we showed a dose-dependent reduction in the infl ammatory infi ltrate in muscles of boys with Duchenne muscular dystrophy in whom dystrophin expression was restored. This fi nding is encouraging because it suggests that the restored dystrophin attenuates the infl ammation that is a hallmark of the disease's pathology; it also suggests that the newly produced dystrophin does not produce novel immunogenic epitopes.
powerful placebo eff ect of open-label studies. Despite these limitations, this observation is encouraging.
In our study, boys remained mostly stable during followup, but because the period during which AVI-4658 was administered was only 12 weeks, we did not observe any signifi cant clinical improvement, and the lack of a study extension was a limitation of our study, since only extended exposure to the drug is able to aff ect progression of the disease. Nevertheless, our results are very encouraging because they prove that doses of 10 mg/kg and 20 mg/kg of AVI-4658, which were very well tolerated, consistently induced dystrophin expression in the seven patients who responded to treatment up to levels typically found in patients with Becker muscular dystrophy or disease of intermediate severity between Duchenne muscular dystrophy and Becker muscular dystrophy. The restoration of the dystrophin-associated glycoprotein complex suggests that the produced dystrophin is functional. Because of the variability of dystrophin restoration, MRI or spectroscopy of muscle are promising methods to assess the eff ect of systemic treatment in Duchenne muscular dystrophy. Recent studies have described the correlation between MRI and the degree of dystrophic muscle changes, 32 the eff ect of exercise in Duchenne muscular dystrophy, 33 and reduction of muscle infl ammation after PMO treatment in dogs. 6 On the basis of our data and recent preclinical data, 31 we expect that extended administration of AVI-4658 at doses of 10 mg/kg or higher will result in suffi cient dystrophin expression to have a positive eff ect on the prevention of muscle degeneration in Duchenne muscular dystrophy. Indeed, chronic administration (1 year) of doses of PMO similar to the one used in our study produced signifi cant improvement in muscle pathology and function in mdx mice. 34 AVI-4658 has the potential to ameliorate the progressive natural history of Duchenne muscular dystrophy and now needs to be investigated in clinical effi cacy trials.
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